Palvella expands QTORIN rapamycin development to angiokeratomas
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/3/2026
- Wall St ends higher as stocks reclaim some shine
- Broadcom raises AI chip forecast as Big Tech keeps writing bigger checks
- Snowflake soars 20% on earnings beat and raised guidance
- Oil settles 1% higher, as US-Iran strikes threaten supplies
- Could Apple’s foldable iPhone be a $14B opportunity? Morgan Stanley weighs in
Palvella Therapeutics (PVLA) PT Raised to $90 at Oppenheimer
September 24, 2025 1:17 PM EDTOppenheimer analyst Trevor Allred raised the price target on Palvella Therapeutics (NASDAQ: PVLA) to $90.00 (from $85.00) while maintaining a Outperform rating.
The analyst comments "Palvella hosted a webcast this morning demonstrating the unmet need and high market potential for Qtorin rapamycin in clinically significant angiokeratomas.... More
